Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Arina V KholinaBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.ORCID 0009-0003-0341-8955
Natalya A BorozdinaBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.ORCID 0000-0002-2320-655X
Victor A PalikovBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.ORCID 0000-0003-2989-4477
Evgeniy S MikhaylovBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.
Irina N KravchenkoBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.ORCID 0000-0002-4662-4332
Renata A DalevichBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.
Irina A PakhomovaBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.
Ekaterina N KazakovaBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.
Maria A TimchenkoInstitute of Theoretical and Experimental Biophysics (RAS), Pushchino 142290, Russia.ORCID 0000-0003-2547-8804
Alexander Ye YegorovInstitute of Theoretical and Experimental Biophysics (RAS), Pushchino 142290, Russia.ORCID 0000-0003-0629-4014
Maxim V MolchanovInstitute of Theoretical and Experimental Biophysics (RAS), Pushchino 142290, Russia.
Artem M ErmakovInstitute of Theoretical and Experimental Biophysics (RAS), Pushchino 142290, Russia.ORCID 0000-0001-7810-0675
Olga Y AntonovaInstitute of Theoretical and Experimental Biophysics (RAS), Pushchino 142290, Russia.ORCID 0000-0003-3311-8745
Olga Y KochetkovaInstitute of Theoretical and Experimental Biophysics (RAS), Pushchino 142290, Russia.ORCID 0000-0003-1758-907X
Natalia M PankratovaInstitute of Mathematical Problems of Biology (RAS)-The Branch of Keldysh Institute of Applied Mathematics of Russian Academy of Sciences, Pushchino 142290, Russia.
Anton N PankratovInstitute of Mathematical Problems of Biology (RAS)-The Branch of Keldysh Institute of Applied Mathematics of Russian Academy of Sciences, Pushchino 142290, Russia.ORCID 0000-0002-1503-0961
Elena V ArshintsevaMedical Emulsions LLC, Pushchino 142290, Russia.
Sergey Y PushkinMedical Emulsions LLC, Pushchino 142290, Russia.
Igor A DyachenkoBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.ORCID 0000-0002-3053-2804
Arkadiy N MurashevBranch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Pushchino 142290, Russia.
Funding
Institute of Theoretical and Experimental Biophysics 075-00223-25-03Medical Emulsions LLC APC
6 · The paper itself
Abstract
Poloxamer 188 is a polymer that is used as a carrier and stabilizer of pharmacological agents. It has been demonstrated to enhance red blood cell and hemoglobin levels in healthy animals and in select clinical cases. The objective of this study was to assess the efficacy of Poloxamer 188 in CBA mice when administered repeatedly in the carboplatin-induced myelosuppression model. The mice were administered carboplatin once at a dose of 100 mg/kg, and then Poloxamer 188 was orally administered daily at doses of 10 mg/kg, 100 mg/kg, 500 mg/kg, and 1000 mg/kg for 7 and 21 days. Poloxamer 188 at a dose of 1000 mg/kg was found to bring the level of 2,3-bisphosphoglycerate in red blood cells close to control level (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Efficacy of Poloxamer 188 in Experimental Myelosuppression Model Induced by Carboplatin in CBA Mice. · full record | OpenQuestion